IT1200970B - Procedimento per stabilizzare un fattore avente effetto necrotizzante sui tumori e soluzione aquosa stabile o polvere che lo contiene - Google Patents

Procedimento per stabilizzare un fattore avente effetto necrotizzante sui tumori e soluzione aquosa stabile o polvere che lo contiene

Info

Publication number
IT1200970B
IT1200970B IT67886/83A IT6788683A IT1200970B IT 1200970 B IT1200970 B IT 1200970B IT 67886/83 A IT67886/83 A IT 67886/83A IT 6788683 A IT6788683 A IT 6788683A IT 1200970 B IT1200970 B IT 1200970B
Authority
IT
Italy
Prior art keywords
stable
powder containing
stabilizing
tnf
aqueous solution
Prior art date
Application number
IT67886/83A
Other languages
English (en)
Other versions
IT8367886A0 (it
Inventor
Hayashi Hiroshi
Komiya Masanobu
Original Assignee
Asahi Chemical Ind
Dainippon Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP57149890A external-priority patent/JPS5939829A/ja
Priority claimed from JP57172178A external-priority patent/JPS5959625A/ja
Application filed by Asahi Chemical Ind, Dainippon Pharmaceutical Co filed Critical Asahi Chemical Ind
Publication of IT8367886A0 publication Critical patent/IT8367886A0/it
Application granted granted Critical
Publication of IT1200970B publication Critical patent/IT1200970B/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/02—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using physical processes
    • A61L2/04—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Environmental Sciences (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Dentistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IT67886/83A 1982-08-31 1983-08-23 Procedimento per stabilizzare un fattore avente effetto necrotizzante sui tumori e soluzione aquosa stabile o polvere che lo contiene IT1200970B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP57149890A JPS5939829A (ja) 1982-08-31 1982-08-31 ガン壊死因子安定化法
JP57172178A JPS5959625A (ja) 1982-09-28 1982-09-28 ガン壊死因子を安定化する方法

Publications (2)

Publication Number Publication Date
IT8367886A0 IT8367886A0 (it) 1983-08-23
IT1200970B true IT1200970B (it) 1989-01-27

Family

ID=26479654

Family Applications (1)

Application Number Title Priority Date Filing Date
IT67886/83A IT1200970B (it) 1982-08-31 1983-08-23 Procedimento per stabilizzare un fattore avente effetto necrotizzante sui tumori e soluzione aquosa stabile o polvere che lo contiene

Country Status (6)

Country Link
US (1) US4457916A (it)
DE (1) DE3331003C2 (it)
ES (1) ES8706446A1 (it)
FR (1) FR2532178B1 (it)
GB (1) GB2126588B (it)
IT (1) IT1200970B (it)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4920196A (en) * 1982-07-30 1990-04-24 Genentech, Inc. Human lymphotoxin
CA1213827A (en) * 1983-04-29 1986-11-12 Ricardo H. Landaburu Process for pasteurizing fibronectin
GB2187191B (en) * 1984-01-30 1989-11-01 Quadrant Bioresources Ltd Protection of proteins and the like
DE3583880D1 (de) * 1984-04-09 1991-10-02 Takeda Chemical Industries Ltd Stabile interleukin-2-zusammensetzung.
JPS60258125A (ja) * 1984-06-06 1985-12-20 Hayashibara Biochem Lab Inc 蛋白性生理活性物質を含有する水溶性乾燥物
US6686455B1 (en) * 1984-07-05 2004-02-03 Genentech, Inc. Tumor necrosis factor
US4650674A (en) * 1984-07-05 1987-03-17 Genentech, Inc. Synergistic cytotoxic composition
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5840522A (en) * 1984-09-20 1998-11-24 Chiron Corporation Recombinant lectins
US4677064A (en) * 1984-11-09 1987-06-30 Cetus Corporation Human tumor necrosis factor
JPS61108400A (ja) * 1984-10-31 1986-05-27 Amano Pharmaceut Co Ltd コレステロ−ルの定量法
US4743680A (en) * 1985-02-01 1988-05-10 New York University Method for purifying antihemophilic factor
EP0193917A3 (en) * 1985-03-06 1987-09-23 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration
US5266333A (en) * 1985-03-06 1993-11-30 American Cyanamid Company Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration of growth hormone
US6084073A (en) * 1985-03-25 2000-07-04 Chiron Corporation Recombinant ricin toxin
US4684623A (en) * 1985-05-02 1987-08-04 The Board Of Trustees Of The Cetus Corporation Use of tumor necrosis factor as a weight regulator
US4931385A (en) * 1985-06-24 1990-06-05 Hygeia Sciences, Incorporated Enzyme immunoassays and immunologic reagents
ATE68524T1 (de) * 1985-07-09 1991-11-15 Quadrant Bioresources Ltd Beschuetzung von proteinen und aehnlichem.
US4868108A (en) * 1985-12-12 1989-09-19 Hygeia Sciences, Incorporated Multiple-antibody detection of antigen
US4822605A (en) * 1986-02-18 1989-04-18 Exovir, Inc. Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like
GB8604983D0 (en) * 1986-02-28 1986-04-09 Biocompatibles Ltd Protein preservation
NL8701143A (nl) * 1986-05-27 1987-12-16 Sandoz Ag Farmaceutische preparaten.
US4678812A (en) * 1986-05-30 1987-07-07 E. I. Du Pont De Nemours And Company Trehalose as stabilizer and tableting excipient
US4762857A (en) * 1986-05-30 1988-08-09 E. I. Du Pont De Nemours And Company Trehalose as stabilizer and tableting excipient
CA1292686C (en) * 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
US5183746A (en) * 1986-10-27 1993-02-02 Schering Aktiengesellschaft Formulation processes for pharmaceutical compositions of recombinant β-
ATE195022T1 (de) 1987-04-27 2000-08-15 Unilever Nv Spezifische bindungstestverfahren
US4808402A (en) * 1987-05-29 1989-02-28 Northwestern University Method and compositions for modulating neovascularization
CA1327161C (en) * 1987-09-01 1994-02-22 Mitsugu Kobayashi Lyophilized pharmaceutical composition of neocarzinostatin derivative
US5756450A (en) * 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
US5215743A (en) * 1988-04-13 1993-06-01 Maninder Singh Tumor necrosis factor formulations
US5078997A (en) * 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5221616A (en) * 1988-07-15 1993-06-22 Quidel Corporation Prevention of spontaneous complement activation in mammalian biological fluids
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5102788A (en) * 1988-11-21 1992-04-07 Hygeia Sciences, Inc. Immunoassay including lyophilized reactant mixture
US5223395A (en) * 1988-12-01 1993-06-29 Centocor, Inc. Immunometric assays for tumor necrosis factor-alpha and methods for preventing the loss of biological activity of tumor necrosis factor-alpha in biological samples
GB8903593D0 (en) 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
USRE38385E1 (en) 1989-02-16 2004-01-13 Nektar Therapeutics Storage of materials
US6352862B1 (en) 1989-02-17 2002-03-05 Unilever Patent Holdings B.V. Analytical test device for imuno assays and methods of using same
US5270057A (en) * 1990-03-20 1993-12-14 Akzo N.V. Stabilized gonadotropin containing preparations
US5384132A (en) * 1990-03-20 1995-01-24 Akzo N.V. Stabilized gonadotropin containing preparations
TW282399B (it) * 1990-05-25 1996-08-01 Takeda Pharm Industry Co Ltd
US5653974A (en) * 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
US5342612A (en) * 1991-12-20 1994-08-30 American Cyanamid Company Compositions for the treatment of mammalian diseases
CA2132328C (en) * 1992-03-24 2000-10-31 Laszlo K. Csatary Vaccine containing live virus for therapy of viral diseases and malignancies
IT1254359B (it) * 1992-05-11 1995-09-14 Serono Cesare Ist Ricerca Composizioni farmaceutiche contenenti il-6
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US6509006B1 (en) 1992-07-08 2003-01-21 Inhale Therapeutic Systems, Inc. Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
ES2179831T3 (es) 1992-09-29 2003-02-01 Inhale Therapeutic Syst Liberacion en los pulmones de fragmentos activos de hormona paratiroidiana.
NZ281112A (en) 1994-03-07 1998-04-27 Inhale Therapeutic Syst Powdered insulin delivered as an aerosol
ATE195322T1 (de) * 1994-03-16 2000-08-15 Mallinckrodt Inc Verwendung von oberflächenaktiven substanzen zur stabilisierung von peptiden und proteinen zur radiopharmazeutischen verwendung
CN1188171C (zh) * 1994-06-02 2005-02-09 廓德伦特控股剑桥有限公司 防止各种特质在再水化或熔化时聚集的方法以及由此获得的组合物
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
CA2213235A1 (en) * 1995-02-15 1996-08-22 The Procter & Gamble Company Crystalline hydroxy waxes as oil in water stabilizers for skin cleansing liquid composition
US6080707A (en) * 1995-02-15 2000-06-27 The Procter & Gamble Company Crystalline hydroxy waxes as oil in water stabilizers for skin cleansing liquid composition
CN1103585C (zh) * 1995-03-14 2003-03-26 普罗克特和甘保尔公司 分散的蒙脱石粘土作为水包油稳定剂用于洁肤液体组合物
WO1996028140A1 (en) 1995-03-14 1996-09-19 The Procter & Gamble Company Dispersed amorphous silica as oil in water stabilizer for skin cleansing liquid composition
US6309671B1 (en) 1995-04-14 2001-10-30 Inhale Therapeutic Systems Stable glassy state powder formulations
GB9508691D0 (en) * 1995-04-28 1995-06-14 Pafra Ltd Stable compositions
US6632648B1 (en) * 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
US5876992A (en) * 1996-07-03 1999-03-02 Molecular Biology Resources, Inc. Method and formulation for stabilization of enzymes
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
IL124275A (en) * 1997-05-02 2002-03-10 Bio Merieux Vitek Inc A method to produce sequences of nucleic acids
US6558901B1 (en) 1997-05-02 2003-05-06 Biomerieux Vitek Nucleic acid assays
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
DE19758073A1 (de) * 1997-12-30 1999-07-01 Schleuning Michael Priv Doz Dr Verfahren zur Kryokonservierung menschlicher und tierischer hämatopoetischer Zellen
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
ATE519494T1 (de) * 2000-02-08 2011-08-15 Allergan Inc Pharmazeutische zusammensetzungen mit botulinum- toxin
US20030138460A1 (en) * 2000-02-08 2003-07-24 Allergan, Inc Methods of treating animals with botulinum toxin pharmaceutical compositions
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
ES2525087T5 (es) 2000-05-10 2018-06-28 Novartis Ag Polvos basados en fosfolípidos para administración de fármacos
PL209826B1 (pl) 2001-10-22 2011-10-31 Dompe Pha R Ma Spa Res & Mfg Sposób współstrącania białka lub polipeptydu
JP2005514393A (ja) 2001-12-19 2005-05-19 ネクター セラピューティクス アミノグリコシドの肺への供給
US7582313B2 (en) * 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
WO2004045376A2 (en) * 2002-11-15 2004-06-03 The General Hospital Corporation Screening methods to identify treatments for autoimmune disease
DE60333228D1 (de) * 2002-12-02 2010-08-12 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
KR100560697B1 (ko) * 2003-08-06 2006-03-16 씨제이 주식회사 알부민을 함유하지 않는 에리스로포이에틴 제제
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
GB2416122A (en) 2004-07-12 2006-01-18 Ipsen Ltd Botulinum neurotoxin composition
US20080102054A1 (en) * 2005-01-18 2008-05-01 Faustman Denise L Compositions Containing Agm Cells And Methods Of Use Thereof
EP1858488B2 (en) 2005-03-14 2022-07-20 Wyeth LLC Tigecycline compositions and methods of preparation
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
FR2902341B1 (fr) * 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
FR2910327B1 (fr) * 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
RU2469739C2 (ru) * 2007-04-26 2012-12-20 БАЙЕР ХЕЛСКЕА ЛЛСи Стабилизация жидких растворов рекомбинантного белка для хранения в замороженном состоянии
FR2930447B1 (fr) * 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
US8183233B2 (en) * 2008-05-15 2012-05-22 Baxter International Inc. Stable pharmaceutical formulations
WO2010144682A1 (en) 2009-06-12 2010-12-16 Micronics, Inc. Rehydratable matrices for dry storage of taq polymerase in a microfluidic device
JP5953229B2 (ja) 2009-06-12 2016-07-20 マイクロニクス， インコーポレイテッド マイクロ流体デバイス内でオンボード試薬を脱水保存する組成物および方法
PL2953634T3 (pl) 2013-02-07 2021-11-22 The General Hospital Corporation Sposoby namnażania lub zubożania limfocytów t-regulatorowych
CN111879948A (zh) 2013-10-17 2020-11-03 综合医院公司 鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物
EP3294773A1 (en) 2015-05-15 2018-03-21 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
WO2017040312A1 (en) 2015-08-28 2017-03-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
US11266730B2 (en) 2015-09-29 2022-03-08 The General Hospital Corporation Methods of treating and diagnosing disease using biomarkers for BCG therapy
CA3023930C (en) 2016-05-13 2025-09-23 The General Hospital Corporation TUMOR-ANTAGONISTIC ANTIBODIES OF THE NECROSIS FACTOR RECEPTOR SUPERFAMILY
GB201612317D0 (en) 2016-07-15 2016-08-31 Philogen Spa Antibody compositions
US11666655B2 (en) 2016-11-28 2023-06-06 Indian Institute Of Technology, Delhi Formulation for stabilizing bio-therapeutics
CN113302205B (zh) 2018-11-15 2024-12-06 综合医院公司 激动性肿瘤坏死因子受体超家族多肽
CN112618482A (zh) * 2019-09-24 2021-04-09 江苏恒瑞医药股份有限公司 新型蛋白制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3637640A (en) * 1970-05-04 1972-01-25 Diagnostic Data Inc Orgotein stabilized with saccharide process and products
DE2652636A1 (de) * 1976-11-19 1978-05-24 Hans Uwe Dr Rer Nat Wolf Verfahren zur stabilisierung von proteinen und verwandten verbindungen waehrend ihrer reinigung, isolierung und lagerung
EP0018609B1 (de) * 1979-04-30 1983-09-21 Hoechst Aktiengesellschaft Gegen Denaturierung beständige, wässrige Protein-Lösungen, Verfahren zu ihrer Herstellung und ihre Verwendung
US4309418A (en) * 1980-03-25 1982-01-05 Sloan-Kettering Research Institute For Cancer Anti-tumor agent from human serum and process

Also Published As

Publication number Publication date
GB2126588B (en) 1986-06-25
ES8706446A1 (es) 1987-06-16
FR2532178B1 (fr) 1986-07-04
FR2532178A1 (fr) 1984-03-02
DE3331003A1 (de) 1984-03-01
ES525228A0 (es) 1987-06-16
DE3331003C2 (de) 1986-07-10
GB8323271D0 (en) 1983-10-05
IT8367886A0 (it) 1983-08-23
US4457916A (en) 1984-07-03
GB2126588A (en) 1984-03-28

Similar Documents

Publication Publication Date Title
IT1200970B (it) Procedimento per stabilizzare un fattore avente effetto necrotizzante sui tumori e soluzione aquosa stabile o polvere che lo contiene
Hearse et al. Diabetes and the survival and recovery of the anoxic myocardium
ES2009704A6 (es) Preservacion de virus.
MX9800438A (es) Formulaciones liquidas que contienen gonadotropina.
BR9407003A (pt) Preparaçao e estabilizaçao de células
IE45026L (en) Veterinary compositions
EP0382355A3 (en) Growth promoting agent for bacteria containing pullulan and/or dextran
ES8505545A1 (es) Un procedimiento para producir un preparado de gamma-interferon estable
EP0147464A4 (en) CHEMICALLY ACTIVE AQUEOUS SOLUTION AND SOLID SUBSTANCE CONTAINING FERROUS IONS.
ES8600051A1 (es) Procedimiento de obtencion de composiciones farmaceuticas a base de derivados de acido glicirretinico.
ATE25807T1 (de) Kochsalzersatz-zusammensetzung.
EP0127673A4 (en) METHOD FOR PRESERVATING LIVING ORGANIC TISSUE BY FREEZING.
MY107455A (en) Taste-modification composition and method for stabilizing taste-modifier
DE3273467D1 (en) Pyridine and pyrazine derivatives, process for the preparation of these compounds, fungicides containing these compounds as active substances, use of these compounds or fungicides to combat fungi in agriculture and in horticulture, and ketones and fungicides containing them
GB1044649A (en) Improvements in or relating to the preservation of blood
ES8501231A1 (es) Un procedimiento para la preparacion de formulaciones granuladas con antibioticos estabilizados.
JPS5765173A (en) Method of freezing fresh food
IT8124519A0 (it) Procedimento per il congelamento ela conservazione di alimenti, e mezzo refrigerante per realizzaretale procedimento.
ES2053573T3 (es) Composiciones rodenticidas que contienen derivados de 1,4-naftoquinona.
AR019271A1 (es) FORMULACION EN FORMA DE SUSPENSION ACUOSA DE PESTICIDA ESFENVALERATO MICROENCAPSULADO Y MÉTODO PARA ESTABILIZAR DICHA FORMULACIoN
ES426414A1 (es) Metodo para producir una preparacion de ciclocitidina seca-da por congelacion.
SU959786A1 (ru) Способ консервировани цельной крови
JPS56144043A (en) Loosening agent for frozen fish
JPS56144047A (en) Loosening agent for frozen fish
Abbott et al. Persistence of adenylate kinase and other enzymes in glycerol extracted muscle

Legal Events

Date Code Title Description
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19970826